www.renibus.comHealthcare / BioTech & PharmaFounded: 2015
Rénibus Therapeutics is a biopharmaceutical and technology company with a mission to prevent disease progression in patients with metabolic or cardiovascular diseases. As a clinical-stage healthcare company, Rénibus Therapeutics is also working on developing an RBT-1 drug which aims to decrease post-operative complications in heart surgery patients or patients with kidney disease. Rénibus Therapeutics was founded by Alvaro Guillem and D. Jeffrey Keyser in 2016 and is headquartered in Southlake, TX.
View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Rénibus Therapeutics.
Become part of the Secondary Marketplace, catering to both individual and institutional investors.